{"id":43652,"date":"2025-10-17T13:50:57","date_gmt":"2025-10-17T05:50:57","guid":{"rendered":"https:\/\/flcube.com\/?p=43652"},"modified":"2025-10-17T13:50:58","modified_gmt":"2025-10-17T05:50:58","slug":"shanghai-junshi-biosciences-secures-fda-approval-for-js207-phase-ii-iii-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43652","title":{"rendered":"Shanghai Junshi Biosciences Secures FDA Approval for JS207 Phase\u202fII\/III Trial"},"content":{"rendered":"\n<p>Shanghai Junshi Biosciences Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/1877:HKG\">HKG: 1877<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688180:SHA\">SHA: 688180<\/a>) today announced that the U.S. Food and Drug Administration (FDA) has granted the company permission to launch an open\u2011label, two\u2011arm, randomized, positive\u2011controlled Phase\u202fII\/III study of its novel bispecific antibody <strong>JS207<\/strong> (PD\u20111\/VEGF) versus the standard of care <strong>nivolumab (Opdivo)<\/strong> in patients with Stage\u202fII\/III, resectable, oncogenic driver\u2011gene\u2011negative (AGA\u2011negative) non\u2011small cell lung cancer (NSCLC).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-highlights\">Key Highlights<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Milestone<\/strong><\/td><td>FDA approval to initiate Phase\u202fII\/III trial<\/td><\/tr><tr><td><strong>Study Design<\/strong><\/td><td>Open\u2011label, 2\u2011arm, randomized, positive\u2011controlled<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>Stage\u202fII\/III, resectable, AGA\u2011negative NSCLC<\/td><\/tr><tr><td><strong>Comparator<\/strong><\/td><td>Nivolumab (Opdivo)<\/td><\/tr><tr><td><strong>Investigational Product<\/strong><\/td><td>JS207 \u2013 humanized anti\u2011PD\u20111\/VEGF bispecific antibody<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-about-js207\">About JS207<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong> \u2013 Dual blockade of PD\u20111 and VEGF pathways, designed to enhance anti\u2011tumor immunity while normalizing tumor vasculature.<\/li>\n\n\n\n<li><strong>Development Status<\/strong> \u2013 Approved for Phase\u202fII\/III entry; multiple Phase\u202fII studies underway across NSCLC, colorectal cancer, triple\u2011negative breast cancer, and hepatocellular carcinoma.<\/li>\n\n\n\n<li><strong>Combination Potential<\/strong> \u2013 Early data suggest synergistic activity when combined with chemotherapy, other monoclonal antibodies, and antibody\u2011drug conjugates (ADCs).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-impact\">Strategic Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011Class Positioning<\/strong> \u2013 JS207 represents a novel therapeutic class that may redefine neoadjuvant therapy for resectable, AGA\u2011negative NSCLC.<\/li>\n\n\n\n<li><strong>Pipeline Expansion<\/strong> \u2013 Successful Phase\u202fII\/III outcomes could unlock broader indications and accelerate global regulatory submissions.<\/li>\n\n\n\n<li><strong>Competitive Advantage<\/strong> \u2013 By targeting both PD\u20111 and VEGF simultaneously, JS207 may overcome resistance mechanisms that limit single\u2011target therapies.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>This press release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) today announced that the U.S. Food&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43656,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,899,296,28,18,900],"class_list":["post-43652","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-hkg-1877","tag-junshi-biosciences","tag-multi-specific-antibodies","tag-pd-1-l1","tag-sha-688180"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai Junshi Biosciences Secures FDA Approval for JS207 Phase\u202fII\/III Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) today announced that the U.S. Food and Drug Administration (FDA) has granted the company permission to launch an open\u2011label, two\u2011arm, randomized, positive\u2011controlled Phase\u202fII\/III study of its novel bispecific antibody JS207 (PD\u20111\/VEGF) versus the standard of care nivolumab (Opdivo) in patients with Stage\u202fII\/III, resectable, oncogenic driver\u2011gene\u2011negative (AGA\u2011negative) non\u2011small cell lung cancer (NSCLC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43652\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Junshi Biosciences Secures FDA Approval for JS207 Phase\u202fII\/III Trial\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43652\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-17T05:50:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-17T05:50:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1703.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43652#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43652\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Junshi Biosciences Secures FDA Approval for JS207 Phase\u202fII\\\/III Trial\",\"datePublished\":\"2025-10-17T05:50:57+00:00\",\"dateModified\":\"2025-10-17T05:50:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43652\"},\"wordCount\":269,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43652#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1703.webp\",\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"HKG: 1877\",\"Junshi Biosciences\",\"Multi-specific antibodies\",\"PD-1\\\/L1\",\"SHA: 688180\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43652#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43652\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43652\",\"name\":\"Shanghai Junshi Biosciences Secures FDA Approval for JS207 Phase\u202fII\\\/III Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43652#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43652#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1703.webp\",\"datePublished\":\"2025-10-17T05:50:57+00:00\",\"dateModified\":\"2025-10-17T05:50:58+00:00\",\"description\":\"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) today announced that the U.S. Food and Drug Administration (FDA) has granted the company permission to launch an open\u2011label, two\u2011arm, randomized, positive\u2011controlled Phase\u202fII\\\/III study of its novel bispecific antibody JS207 (PD\u20111\\\/VEGF) versus the standard of care nivolumab (Opdivo) in patients with Stage\u202fII\\\/III, resectable, oncogenic driver\u2011gene\u2011negative (AGA\u2011negative) non\u2011small cell lung cancer (NSCLC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43652#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43652\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43652#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1703.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1703.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shanghai Junshi Biosciences Secures FDA Approval for JS207 Phase\u202fII\\\/III Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43652#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Junshi Biosciences Secures FDA Approval for JS207 Phase\u202fII\\\/III Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Junshi Biosciences Secures FDA Approval for JS207 Phase\u202fII\/III Trial - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) today announced that the U.S. Food and Drug Administration (FDA) has granted the company permission to launch an open\u2011label, two\u2011arm, randomized, positive\u2011controlled Phase\u202fII\/III study of its novel bispecific antibody JS207 (PD\u20111\/VEGF) versus the standard of care nivolumab (Opdivo) in patients with Stage\u202fII\/III, resectable, oncogenic driver\u2011gene\u2011negative (AGA\u2011negative) non\u2011small cell lung cancer (NSCLC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43652","og_locale":"en_US","og_type":"article","og_title":"Shanghai Junshi Biosciences Secures FDA Approval for JS207 Phase\u202fII\/III Trial","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=43652","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-17T05:50:57+00:00","article_modified_time":"2025-10-17T05:50:58+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1703.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43652#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43652"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Junshi Biosciences Secures FDA Approval for JS207 Phase\u202fII\/III Trial","datePublished":"2025-10-17T05:50:57+00:00","dateModified":"2025-10-17T05:50:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43652"},"wordCount":269,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43652#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1703.webp","keywords":["Cancer","Clinical trial approval \/ initiation","HKG: 1877","Junshi Biosciences","Multi-specific antibodies","PD-1\/L1","SHA: 688180"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43652#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43652","url":"https:\/\/flcube.com\/?p=43652","name":"Shanghai Junshi Biosciences Secures FDA Approval for JS207 Phase\u202fII\/III Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43652#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43652#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1703.webp","datePublished":"2025-10-17T05:50:57+00:00","dateModified":"2025-10-17T05:50:58+00:00","description":"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) today announced that the U.S. Food and Drug Administration (FDA) has granted the company permission to launch an open\u2011label, two\u2011arm, randomized, positive\u2011controlled Phase\u202fII\/III study of its novel bispecific antibody JS207 (PD\u20111\/VEGF) versus the standard of care nivolumab (Opdivo) in patients with Stage\u202fII\/III, resectable, oncogenic driver\u2011gene\u2011negative (AGA\u2011negative) non\u2011small cell lung cancer (NSCLC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43652#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43652"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43652#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1703.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1703.webp","width":1080,"height":608,"caption":"Shanghai Junshi Biosciences Secures FDA Approval for JS207 Phase\u202fII\/III Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43652#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Junshi Biosciences Secures FDA Approval for JS207 Phase\u202fII\/III Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1703.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43652","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43652"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43652\/revisions"}],"predecessor-version":[{"id":43657,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43652\/revisions\/43657"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43656"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43652"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43652"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43652"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}